SOLVE THERAPEUTICS

HQ - San Diego

Summary

Solve is developing novel antibody-drug conjugates engineered for selectivity and optimized payload delivery, as well as novel patient-selection diagnostics.

Deals Overview

Total Deals1

Valued Deals1

Total Value£ 91 M

Avg. Deal Size£ 91 M

Market Context

Senior Management

Dave Johnson
CEO & Co-Founder